Blueprint Medicines Corporation (BPMC)

[protagonist12]

Blueprint Medicines (BPMC) expects to raise $115 million in an initial public offering (IPO) on Thursday, April 30th. The company will be issuing 7,200,000 shares at a price of $15.00-$17.00 per share.

Blueprint Medicines has a market cap of $398 million.

Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines provided the following description of their company for its IPO: “We are a biopharmaceutical company focused on improving the lives of patients with genomically defined diseases driven by abnormal kinase activation. Our approach is to systematically and reproducibly identify kinases that are drivers of genomically defined diseases and to craft drug candidates with therapeutic windows that provide significant and durable clinical responses to patients. This integrated biology and chemistry approach enables us to drug known kinases that have been difficult to inhibit selectively and also identify, characterize and drug novel kinase targets.”.

Blueprint Medicines was founded in 2008 and has 60 employees. The company is located at 215 First Street, Cambridge, MA 02142,, US and can be reached via phone at [phone] or on the web at www.blueprintmedicines.com.